Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors
Key Highlights
- ➤Curis (CRIS) prices $8.5 million private placement at effective $0.51 per share.
- ➤Investors receive warrants for 16,666,680 shares exercisable at $0.60 after six months.
- ➤Curis cuts January and August warrant exercise prices to $0.60.
- ➤Proceeds expected to fund operations through initial CLL data in December 2026.
- ➤Net proceeds will fund research, development, working capital and general corporate purposes.
Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors PR Newswire
LEXINGTON, Mass., Oct. 16, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS) ("Curis" or the "Company"), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it has entered into securities purchase agreements with certain existing healthcare focused institutional investors for the purchase and sale of 16,666,680 shares of common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and common warrants to purchase up to 16,666,680 shares of common stock at an effective combined price of $0.51 per share (or pre-funded warrant) and accompanying common warrant (the "Offering"). The common warrants have an exercise price of $0.60 per share, will be exercisable six months following their issuance and will expire five and a half years from the issuance date. The pre-funded warrants have an exercise price of $0.01 per share and will be exercisable immediately until exercised in full.
Get started
Create a free account to read the full story.